$50.52
1.96% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Stock price

$50.52
-1.09 2.11% 1M
-25.17 33.25% 6M
-21.51 29.86% YTD
-26.36 34.29% 1Y
-13.07 20.55% 5Y
+26.00 106.01% 10Y
+39.21 346.59% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-1.01 1.96%
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Key metrics

Market capitalization $7.92b
Enterprise Value $8.11b
P/E (TTM) P/E ratio 61.61
EV/FCF (TTM) EV/FCF 36.73
EV/Sales (TTM) EV/Sales 6.71
P/S ratio (TTM) P/S ratio 6.55
P/B ratio (TTM) P/B ratio 3.92
Dividend yield 0.63%
Last dividend (FY25) $0.32
Revenue growth (TTM) Revenue growth -15.54%
Revenue (TTM) Revenue $1.21b
EBIT (operating result TTM) EBIT $218.20m
Free Cash Flow (TTM) Free Cash Flow $220.76m
Cash position $140.67m
EPS (TTM) EPS $0.82
P/E forward 57.63
P/S forward 6.50
EV/Sales forward 6.66
Short interest 5.52%
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Bio-Techne Corporation forecast:

12x Buy
67%
6x Hold
33%

Analyst Opinions

18 Analysts have issued a Bio-Techne Corporation forecast:

Buy
67%
Hold
33%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,209 1,209
16% 16%
100%
- Direct Costs 406 406
14% 14%
34%
803 803
16% 16%
66%
- Selling and Administrative Expenses 487 487
4% 4%
40%
- Research and Development Expense 97 97
19% 19%
8%
329 329
25% 25%
27%
- Depreciation and Amortization 111 111
0% 0%
9%
EBIT (Operating Income) EBIT 218 218
33% 33%
18%
Net Profit 132 132
48% 48%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
PRNewsWire
4 days ago
ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.
Neutral
PRNewsWire
16 days ago
MINNEAPOLIS , May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference June 3, 2025 2:40 PM CDT Jefferies Global Healthcare Conference June 4, 2025 3:45 PM EDT Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM EDT A live webcast of t...
Neutral
PRNewsWire
about one month ago
ST. PAUL, Minn. , May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA).
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today